Supplement to Support the Development of a New Multiplexed Imaging Tool using Raman Spectroscopy for Breast Cancer
Supplement to Support the Development of a New Multiplexed Imaging Tool using Raman Spectroscopy for Breast Cancer
批准号:
10839117
负责人:
Cristina L. Zavaleta
金额:
$6.55万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-08-16 至 2026-03-31
关键词:
AffinityAntibody AvidityBar CodesBindingBiological MarkersBreast Cancer PatientCellular AssayChargeChemicalsClinicalCollectionConsumptionContrast MediaDetectionDevelopmentDiagnosisDiseaseEnsureFailureGoldHealth Care CostsHistologyImageImaging DeviceImaging TechniquesImmunotherapyIn VitroIndividualLigandsMapsMolecularMolecular ProfilingMonoclonal AntibodiesMorbidity - disease rateNanosphereOncologistPathologistPathologyPatient-Focused OutcomesPatientsPhysiciansPrediction of Response to TherapyPropertyProteinsPublic HealthRaman Spectrum AnalysisRegimenResearchSamplingSilicon DioxideSpecimenStainsSurfaceTechniquesTechnologyTestingTherapeuticTimeTissuesWomanantibody conjugatecancer cellcareer developmentchemical propertyclinical applicationclinical translationcontrast imagingdesigndetection sensitivityeffective therapyimaging approachimprovedindividual patientineffective therapiesmalignant breast neoplasmmolecular imagingmultiplexed imagingnanoparticleneoplastic cellnoveloptical imagingoverexpressionpathology imagingpatient stratificationpredicting responseprogrammed cell death ligand 1programmed cell death protein 1receptor expressionside effectsingle cell analysisspectrographtargeted biomarkertargeted treatmenttherapeutically effectivetooltreatment optimizationtreatment responsetumortumor heterogeneity
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Breast cancer, in particular, is very heterogeneous with many morphological and molecular features that present
differently across patients. Failure to fully understand the molecular expression and tumor heterogeneity across a
patient's tumor can lead to administration of ineffective therapies that increase patient morbidity and healthcare
costs. The -omics era has made it possible to identify several new molecular markers involved in breast cancer
development, survival, invasion and even predicting treatment response. We currently lack an easy way to obtain
high content molecular information while providing high resolution spatial profiling across a patient's tumor. This
proposal aims to provide physicians with an entirely new multiplexed molecular imaging strategy that has the potential
to offer both high content molecular expression and spatial profiling in a single histology image. Raman
spectroscopy in conjunction with surface enhanced Raman scattering (SERS) nanoparticles is an optical imaging
technique that can offer unsurpassed sensitivity (on the order of fM) and multiplexing capabilities to the field of
histology imaging with the potential to provide rich molecular details on the microscopic level. Clinicians will be
able to utilize the imaging strategy on the same tissue sections prepared for histology. Incorporating it into the
pathology workfiow could enable physicians to better understand the patient's tumor type and stratify patients to
receive the most effective therapeutic regimen possible. This unique histology imaging strategy also has the
potential to identify new molecular trends in patient's tissue samples that could be used to predict how aggressive
their tumor is or how well the patient is likely to respond to given therapies. This innovative ex-vivo diagnostic
strategy has a high likelihood for clinical translation; offering rapid whole tissue section imaging for multiple
biomarkers simultaneously. Our approach begins by developing a new set of sensitive SERS nanoparticle (NP)
batches, each designed with a unique spectral barcode to enable simultaneous molecular interrogation of an entire
tissue sample within a single image. After fabrication and characterization of our newly developed multiplexed SERS
nano particles, we will test their multiplexed imaging capabilities and tumor targeting efficiency in various breast cancer
models including cell culture and on de-identified tissue sections. Our nanoparticles will actively target multiple breast
cancer receptors through chemically conjugated targeting ligands. We will assess the tumor targeting efficiency of
our newly developed nanoparticles with microscopic Raman imaging tools and compare with gold standard
immunohistochemistry {IHC) staining. These results will be an important step in the clinical translation of this new
multiplexed Raman imaging approach; to provide rapid spatial molecular profiling of a given tumor while enabling
a more effective personalized therapy to the patient.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1039/d3an01298k
发表时间:
2023-10
期刊:
The Analyst
影响因子:
--
作者:
[O. Eremina;Sarah Schaefer;Alexander T Czaja;Samer Awad;Matthew A Lim;Cristina Zavaleta]
通讯作者:
O. Eremina;Sarah Schaefer;Alexander T Czaja;Samer Awad;Matthew A Lim;Cristina Zavaleta
A New Multimodal Molecular Imaging Approach to Guide Intra-Operative Tumor Resection and Post-Operative Treatment Planning
-
批准号:10578468
-
项目类别:
-
资助金额:$62.76万
-
财政年份:2023
-
负责人:Cristina L. Zavaleta
-
依托单位:
A New Strategy for Cancer Detection using Raman Spectroscopy with Nanoparticles
-
批准号:8700750
-
项目类别:
-
资助金额:$19.39万
-
财政年份:2014
-
负责人:Cristina L. Zavaleta
-
依托单位:
海外基金